# US 2021/0261583 A1 · Synthetic Cytotoxic Molecules, Drugs, Methods of Their Synthesis and Methods of Treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261583 A1
- Document ID: US20210261583A1
- Status: Published application
- Kind: A1
- Application number: 17/252,226
- Filed: 2019-06-14
- Published: 2021-08-26
- Earliest claimed: 2018-06-14
- Assignees: The Regents of the University of California; Universite de Montreal
- Applicants: The Regents of the University of California; Universite de Montreal
- Inventors: Aimee Edinger; Stephen Hanessian
- Web page: https://patentgrep.com/patent/US20210261583A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07F 9/572: Five-membered rings
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 207/06: with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D 207/08: with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D 207/12: Oxygen or sulfur atoms
- C07D 487/04: Ortho-condensed systems
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Small molecules compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.

## Claims

### Claim 1

A compound of formula
wherein:
R1 is a functional group selected from H, an alkyl chain, OH, (CH2)nOH, CHOH-alkyl, CHOH-alkyne, (CH2)nOR′, (CH2)nPO(OH)2 and esters thereof, CH═CHPO(OH)2 and esters thereof, (CH2CH2)nPO(OH)2 and esters thereof, and (CH2)nOPO(OH)2 and esters thereof, (CH2)nPO3 and esters thereof, where R′ is an alkyl, alkene or alkyne;
R2 is an aliphatic chain (C6-C14);
R3 is a mono-, di-, tri- or tetra-aromatic substituent comprising hydrogen, halogen, alkyl, alkoxy, azide (N3), ether, NO2, cyanide (CN), or a combination thereof;
R4 is a functional group selected from H, alkyl including methyl (Me), tert-butyloxycarbonyl, or acyl;
X− is an anion of the suitable acid;
n is an independently selected integer selected from 1, 2, or 3;
m is an independently selected integer selected from 0, 1 or 2; and comprising
wherein the linking group connecting the phenyl ring to the azacycle may optionally include one or more functional groups selected from the following:
a polar group in the alpha, beta or gamma position with regard to the azacycle selected from carbonyls (C═O), alcohols (CHOH), and alkoxys; and
a cyclic carbon chain extending from the alpha, beta or gamma positions with regard to the azacycle back to the N of the azacycle;
and a combination thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The compound of claim 1, wherein the compound is capable of having a cytotoxic or cytostatic effect on human neoplastic cells, and wherein the cytotoxic effect is defined by a reduction in the percentage of viable human neoplastic cells and the cytostatic effect is defined by reduction of proliferation of neoplastic cells.

### Claim 7 (depends on 6)

The compound of claim 6, wherein the cytotoxic or cytostatic effect is achieved with a local 50% inhibitory concentration (IC50) of less than twenty micromolar, wherein the local IC50 is defined by the concentration of the compound that reduces the percentage of viable human neoplastic cells by 50%.

### Claim 8 (depends on 6)

The compound of claim 6, wherein the human neoplastic cells are at least one of the following:
derived from at least one neoplasm, and wherein the at least one neoplasm is selected from the group consisting of: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), anal cancer, astrocytomas, basal cell carcinoma, bile duct cancer, bladder cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia (CLL) chronic myelogenous leukemia (CML), chronic myeloproliferative neoplasms, colorectal cancer, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing sarcoma, fallopian tube cancer, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, hairy cell leukemia, hepatocellular cancer, Hodgkin lymphoma, hypopharyngeal cancer, Kaposi sarcoma, Kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, Merkel cell cancer, mesothelioma, mouth cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, osteosarcoma, ovarian cancer, pancreatic cancer, pancreatic neuroendocrine tumors, pharyngeal cancer, pituitary tumor, prostate cancer, rectal cancer, renal cell cancer, retinoblastoma, skin cancer, small cell lung cancer, small intestine cancer, squamous neck cancer, T-cell lymphoma, testicular cancer, thymoma, thyroid cancer, uterine cancer, vaginal cancer, and vascular tumors; and
characterized by one of: fast-growing, aggressive, Warburg-phenotypic, malignant, Ras-positive, PTEN-negative, having PI 3-kinase mutations, benign, metastatic, or nodular.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The compound of claim 1, wherein the compound is at least one of the following:
capable of exerting bioenergetic stress on human cells, wherein the bioenergetic stress is characterized by a decrease of at least one nutrient available to the human cells, and wherein the at least one nutrient is selected from one or more of the group: glucose, amino acids, nucleotides, and lipids; and
capable of inhibiting growth of a tumor comprised of human neoplastic cells, wherein growth is defined by at least one growth assessment, and wherein the at least one growth assessment is selected from the group consisting of: an increase in tumor diameter, an increase in tumor bioluminescence, an increase in tumor volume, an increase in tumor mass, or neoplastic cell proliferation.

### Claim 11 (depends on 10)

The compound of claim 10, wherein the human cells are comprised of neoplastic and non-neoplastic cells, and wherein the bioenergetic stress results in greater percentage of cell death in the neoplastic cells relative to non-neoplastic cells.

### Claim 12

(canceled)

### Claim 13

A medicament for the treatment of a human disorder comprising:
a pharmaceutical formulation containing a therapeutically effective amount of one or more small molecule compounds having the formula
wherein:
R1 is a functional group selected from H, an alkyl chain, OH, (CH2)nOH, CHOH-alkyl, CHOH-alkyne, (CH2)nOR', (CH2)nPO(OH)2 and esters thereof, CH═CHPO(OH)2 and esters thereof, (CH2CH2)nPO(OH)2 and esters thereof, and (CH2)nOPO(OH)2 and esters thereof, (CH2)nPO3 and esters thereof, where R′ is an alkyl, alkene or alkyne;
R2 is an aliphatic chain (C6-C14);
R3 is a mono-, di-, tri- or tetra-aromatic substituent comprising hydrogen, halogen, alkyl, alkoxy, azide (N3), ether, NO2, cyanide (CN), or a combination thereof;
R4 is a functional group selected from H, alkyl including methyl (Me), tert-butyloxycarbonyl, or acyl;
X− is an anion of the suitable acid;
n is an independently selected integer selected from 1, 2, or 3;
m is an independently selected integer selected from 0, 1 or 2; and comprising
wherein the linking group connecting the phenyl ring to the azacycle may
optionally include one or more functional groups selected from the following:
a polar group in the alpha, beta or gamma position with regard to the azacycle selected from carbonyls (C═O), alcohols (CHOH), and alkoxys; and
a cyclic carbon chain extending from the alpha, beta or gamma positions with regard to the azacycle back to the N of the azacycle,
or a combination thereof.

### Claim 14 (depends on 13)

The medicament of claim 13, wherein the one or more compounds is selected from the group consisting of:

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 13)

The medicament of claim 13, wherein the human disorder is at least one neoplasm, and wherein the at least one neoplasm is selected the group consisting of: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), anal cancer, astrocytomas, basal cell carcinoma, bile duct cancer, bladder cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia (CLL) chronic myelogenous leukemia (CML), chronic myeloproliferative neoplasms, colorectal cancer, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing sarcoma, fallopian tube cancer, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, hairy cell leukemia, hepatocellular cancer, Hodgkin lymphoma, hypopharyngeal cancer, Kaposi sarcoma, Kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, Merkel cell cancer, mesothelioma, mouth cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, osteosarcoma, ovarian cancer, pancreatic cancer, pancreatic neuroendocrine tumors, pharyngeal cancer, pituitary tumor, prostate cancer, rectal cancer, renal cell cancer, retinoblastoma, skin cancer, small cell lung cancer, small intestine cancer, squamous neck cancer, T-cell lymphoma, testicular cancer, thymoma, thyroid cancer, uterine cancer, vaginal cancer, and vascular tumors.

### Claim 19 (depends on 13)

The medicament of claim 13, wherein the one or more compounds is at least one of the following:
capable of having a cytotoxic or cytostatic effect on human neoplastic cells, and wherein the cytotoxic effect is defined by a reduction in the percentage of viable human neoplastic cells and the cytostatic effect is defined by reduction of proliferation of neoplastic cells; and
capable of exerting bioenergetic stress on human cells, wherein the bioenergetic stress is characterized by a decrease of at least one nutrient available to the human cells, and wherein the at least one nutrient is selected from the group consisting of: glucose, amino acids, nucleotides, and lipids.

### Claim 20 (depends on 19)

The medicament of claim 19, wherein the cytotoxic or cytostatic effect is achieved with a local 50% inhibitory concentration (IC50) of less than twenty micromolar, wherein the local IC50 is defined by the concentration of the compound that reduces the percentage of viable human neoplastic cells by 50%.

### Claim 21 (depends on 13)

The medicament of claim 13, wherein the medicament is for the treatment of a neoplasm characterized by at least one of: fast-growing, aggressive, Warburg-phenotypic, malignant, Ras-positive, PTEN-negative, having PI 3-kinase mutations, benign, metastatic, or nodular.

### Claim 22

(canceled)

### Claim 23 (depends on 19)

The medicament of claim 19, wherein the human cells are comprised of neoplastic and non-neoplastic cells, and wherein the bioenergetic stress results in greater percentage of cell death in the neoplastic cells relative to the non-neoplastic cells.

### Claim 24 (depends on 13)

The medicament of claim 13, wherein the pharmaceutical formulation at least one of the following:
is capable of inhibiting growth of a tumor comprising human neoplastic cells, wherein growth is defined by at least one growth assessment, and wherein the at least one growth assessment is selected from one or more of the group: an increase in tumor diameter, an increase in tumor bioluminescence, an increase in tumor volume, an increase in tumor mass, and neoplastic cell proliferation; and
further comprises at least one cytotoxic FDA-approved compound for the treatment of a neoplasm.

### Claim 25

(canceled)

### Claim 26 (depends on 23)

The medicament of claim 23, wherein the at least one cytotoxic FDA-approved compound is selected from the group consisting of:
methotrexate, gemcitabine, tamoxifen, taxol, docetaxel, and enzalutamide.

### Claim 27

A method of treatment of a human disorder comprising:
administering a pharmaceutical formulation to a human subject, the pharmaceutical formulation containing a therapeutically effective amount of one or more small molecule compounds having the formula
wherein:
R1 is a functional group selected from H, an alkyl chain, OH, (CH2)nOH, CHOH-alkyl, CHOH-alkyne, (CH2)nOR', (CH2)nPO(OH)2 and esters thereof, CH═CHPO(OH)2 and esters thereof, (CH2CH2)nPO(OH)2 and esters thereof, and (CH2)nOPO(OH)2 and esters thereof, (CH2)nPO3 and esters thereof, where R′ is an alkyl, alkene or alkyne;
R2 is an aliphatic chain (C6-C14);
R3 is a mono-, di-, tri- or tetra-aromatic substituent comprising hydrogen, halogen, alkyl, alkoxy, azide (N3), ether, NO2, cyanide (CN), or a combination thereof;
R4 is a functional group selected from H, alkyl including methyl (Me), tert-butyloxycarbonyl, or acyl;
X− is an anion of the suitable acid;
n is an independently selected integer selected from 1, 2, or 3;
m is an independently selected integer selected from 0, 1 or 2; and comprising
wherein the linking group connecting the phenyl ring to the azacycle may
optionally include one or more functional groups selected from the following:
a polar group in the alpha, beta or gamma position with regard to the azacycle selected from carbonyls (C═O), alcohols (CHOH) , and alkoxys; and
a cyclic carbon chain extending from the alpha, beta or gamma positions with regard to the azacycle back to the N of the azacycle,
or a combination thereof.

### Claim 28 (depends on 27)

The method of claim 27, wherein the one or more compounds is selected from the group consisting of:

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 27)

The method of claim 27, further comprising diagnosing the human subject with at least one human disorder.

### Claim 33 (depends on 32)

The method of claim 32, wherein the at least one human disorder is at least one of the following:
a neoplasm, and wherein the neoplasm is selected from one or more of the group:
acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), anal cancer, astrocytomas, basal cell carcinoma, bile duct cancer, bladder cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia (CLL) chronic myelogenous leukemia (CML), chronic myeloproliferative neoplasms, colorectal cancer, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing sarcoma, fallopian tube cancer, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, hairy cell leukemia, hepatocellular cancer, Hodgkin lymphoma, hypopharyngeal cancer, Kaposi sarcoma, Kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, Merkel cell cancer, mesothelioma, mouth cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, osteosarcoma, ovarian cancer, pancreatic cancer, pancreatic neuroendocrine tumors, pharyngeal cancer, pituitary tumor, prostate cancer, rectal cancer, renal cell cancer, retinoblastoma, skin cancer, small cell lung cancer, small intestine cancer, squamous neck cancer, T-cell lymphoma, testicular cancer, thymoma, thyroid cancer, uterine cancer, vaginal cancer, and vascular tumors; and
characterized by at least one neoplasm characterization, and wherein the at least one neoplasm characterization is selected from one or more of the group: fast-growing, aggressive, Warburg-phenotypic, malignant, Ras-positive, PTEN-negative, having PI 3-kinase mutations, benign, metastatic, or nodular.

### Claim 34 (depends on 27)

The method of treatment of claim 27, wherein the pharmaceutical formulation is at least one of the following:
inhibits growth of a tumor comprising human neoplastic cells, wherein growth is defined by at least one growth assessment, and wherein the at least one growth assessment is selected from one or more of the group: an increase in tumor diameter, an increase in tumor bioluminescence, an increase in tumor volume, an increase in tumor mass, and neoplastic cell proliferation; and
combined with at least one cytotoxic FDA-approved compound.

### Claim 35

(canceled)

### Claim 36 (depends on 27)

The method of treatment of claim 27, where in the treatment is combined with an FDA-approved standard of care.

### Claim 37

(canceled)

### Claim 38 (depends on 34)

The method of treatment of claim 34, wherein the at least one cytotoxic FDA-approved compound is selected from the group consisting of:
methotrexate, gemcitabine, tamoxifen, taxol, docetaxel, and enzalutamide.

### Claim 39

A compound having the formula:
